Siesta Pharmaceuticals

Siesta Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for sleep-wake disorders. Based in San Diego, California, the company was founded by prominent sleep researchers to address the limitations of current treatments for narcolepsy and idiopathic hypersomnia. Their lead candidate, SP-001, is a novel formulation of sodium oxybate designed to optimize drug delivery and improve patient outcomes. By focusing on high-unmet-need areas within sleep medicine, Siesta Pharmaceuticals aims to provide more effective and better-tolerated options for patients suffering from excessive daytime sleepiness and disrupted sleep patterns. The company leverages proprietary formulation technology to enhance the pharmacokinetic profile of its therapies while reducing the sodium burden associated with standard-of-care oxybate treatments.